CREBBP: A Potential Drug Target and Biomarker for Alzheimer's Disease

Target Name: CREBBP

NCBI ID: G1387

CREBBP

CREBBP: A Potential Drug Target and Biomarker for Alzheimer's Disease

CREBBP (CREBBP variant 1) is a protein that is expressed in the brain and is known for its role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein is composed of four subunits, which are involved in the regulation of neuronal communication and the formation of memory.

CREBBP has been identified as a potential drug target for the treatment of Alzheimer's disease and other neurological disorders. This is because the protein is involved in the formation of beta-amyloid plaques, which are thought to contribute to the development of Alzheimer's disease. Additionally, CREBBP has been shown to be involved in the regulation of neurotransmitter release, which is important for the function of neurons.

Research has also shown that CREBBP is involved in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. This is important for the formation of new memories and the regulation of learning and memory.

In addition to its potential as a drug target, CREBBP has also been shown to be a potential biomarker for the diagnosis of Alzheimer's disease. This is because the protein is often reduced in the brains of people with Alzheimer's disease, and may be a useful diagnostic marker for this disease.

One way that researchers are studying CREBBP is to use techniques such as biochemical assays and live-cell imaging to understand its role in the development and progression of Alzheimer's disease. They are also using animal models of the disease to study the effects of drugs on the expression and function of CREBBP.

While further research is needed to fully understand the role of CREBBP in the development and progression of Alzheimer's disease, studies have shown that it is an important protein that may be a potential drug target and biomarker for this disease. Further research is likely to shed light on its role and its potential as a treatment for this debilitating and progressive disorder.

Protein Name: CREB Binding Protein

Functions: Acetylates histones, giving a specific tag for transcriptional activation (PubMed:24616510). Also acetylates non-histone proteins, like DDX21, FBL, IRF2, MAFG, NCOA3, POLR1E/PAF53 and FOXO1 (PubMed:10490106, PubMed:11154691, PubMed:12738767, PubMed:12929931, PubMed:9707565, PubMed:24207024, PubMed:28790157, PubMed:30540930, PubMed:35675826). Binds specifically to phosphorylated CREB and enhances its transcriptional activity toward cAMP-responsive genes. Acts as a coactivator of ALX1. Acts as a circadian transcriptional coactivator which enhances the activity of the circadian transcriptional activators: NPAS2-BMAL1 and CLOCK-BMAL1 heterodimers (PubMed:14645221). Acetylates PCNA; acetylation promotes removal of chromatin-bound PCNA and its degradation during nucleotide excision repair (NER) (PubMed:24939902). Acetylates POLR1E/PAF53, leading to decreased association of RNA polymerase I with the rDNA promoter region and coding region (PubMed:24207024). Acetylates DDX21, thereby inhibiting DDX21 helicase activity (PubMed:28790157). Acetylates FBL, preventing methylation of 'Gln-105' of histone H2A (H2AQ104me) (PubMed:30540930). Functions as a transcriptional coactivator for SMAD4 in the TGF-beta signaling pathway (PubMed:25514493)

The "CREBBP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CREBBP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets